CA2230540A1 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds Download PDF

Info

Publication number
CA2230540A1
CA2230540A1 CA002230540A CA2230540A CA2230540A1 CA 2230540 A1 CA2230540 A1 CA 2230540A1 CA 002230540 A CA002230540 A CA 002230540A CA 2230540 A CA2230540 A CA 2230540A CA 2230540 A1 CA2230540 A1 CA 2230540A1
Authority
CA
Canada
Prior art keywords
group
compound
alkyl
hydrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002230540A
Other languages
English (en)
French (fr)
Inventor
Vinod Francis Patel
James Edward Ray
John Eldon Toth
Richard Elliott Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawaii
Wayne State University
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2230540A1 publication Critical patent/CA2230540A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002230540A 1995-08-30 1996-08-30 Pharmaceutical compounds Abandoned CA2230540A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US293595P 1995-08-30 1995-08-30
US60/002,935 1995-08-30

Publications (1)

Publication Number Publication Date
CA2230540A1 true CA2230540A1 (en) 1997-03-06

Family

ID=21703268

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002230540A Abandoned CA2230540A1 (en) 1995-08-30 1996-08-30 Pharmaceutical compounds
CA002246117A Abandoned CA2246117A1 (en) 1995-08-30 1996-08-30 Cryptophycins from aberrant biosynthesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002246117A Abandoned CA2246117A1 (en) 1995-08-30 1996-08-30 Cryptophycins from aberrant biosynthesis

Country Status (6)

Country Link
EP (2) EP0850316A4 (ja)
JP (2) JP2000501067A (ja)
AU (2) AU6904896A (ja)
BR (1) BR9610214A (ja)
CA (2) CA2230540A1 (ja)
WO (2) WO1997008334A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6904896A (en) * 1995-08-30 1997-03-19 Eli Lilly And Company Pharmaceutical compounds
JP2000502351A (ja) * 1995-12-22 2000-02-29 イーライ・リリー・アンド・カンパニー 医薬化合物
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
US5977387A (en) * 1996-08-30 1999-11-02 Eli Lilly And Company Process for preparing pharmaceutical compounds
JP2001502297A (ja) * 1996-08-30 2001-02-20 イーライ・リリー・アンド・カンパニー 医薬用化合物
EP0934065B1 (en) * 1996-08-30 2006-06-07 University Of Hawaii Novel cryptophycin derivatives as anti-neoplastic agents
WO1998009601A2 (en) * 1996-09-06 1998-03-12 Eli Lilly And Company Process to prepare pharmaceutical compounds
JP2001506970A (ja) * 1996-09-06 2001-05-29 イーライ・リリー・アンド・カンパニー 方法及び新規な中間体
JP2002513403A (ja) * 1997-02-26 2002-05-08 イーライ・リリー・アンド・カンパニー 医薬品化合物を製造するための選択的なエポキシ化方法
WO1998038178A1 (en) * 1997-02-26 1998-09-03 Eli Lilly And Company Tripeptide and tetrapeptide pharmaceutical compounds
EP0870501A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Use of specific cryptophycin derivatives for the manufacture of a medicament in the treatment of fungal infections
EP0870506A1 (en) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprising a cryptophycin compound in combination with a synchronizing or activating agent for treating cancer
US6180679B1 (en) * 1998-04-07 2001-01-30 Eli Lilly And Company Method for treating fungal infections
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
EP2266607A3 (en) 1999-10-01 2011-04-20 Immunogen, Inc. Immunoconjugates for treating cancer
WO2003077906A1 (en) * 2002-03-18 2003-09-25 Nihon University Cyclic etheramine derivatives as medicaments for malignant tumors
US7229814B2 (en) * 2004-05-05 2007-06-12 Regents Of The University Of Minnesota Nucleic acids and polypeptides involved in the production of cryptophycin
JPWO2007000994A1 (ja) * 2005-06-28 2009-01-22 中外製薬株式会社 抗ｈｃｖ作用を有する化合物の製造方法
CN103724290B (zh) * 2013-11-15 2015-04-29 浙江大学 一种环肽化合物clavatustide A及其产生菌、制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868208A (en) * 1988-07-15 1989-09-19 Merck & Co., Inc. Antifungal agent and method
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
US5952298A (en) * 1993-12-21 1999-09-14 The University Of Hawaii Cryptophycins
AP737A (en) * 1995-03-07 1999-03-15 Univ Hawaii New cryptophycins from synthesis.
AU6904896A (en) * 1995-08-30 1997-03-19 Eli Lilly And Company Pharmaceutical compounds

Also Published As

Publication number Publication date
EP0850316A1 (en) 1998-07-01
AU6904896A (en) 1997-03-19
AU7109096A (en) 1997-03-19
EP0850316A4 (en) 2000-08-23
AU709828B2 (en) 1999-09-09
CA2246117A1 (en) 1997-03-06
BR9610214A (pt) 1999-06-15
WO1997008334A1 (en) 1997-03-06
JP2000507805A (ja) 2000-06-27
EP0850057A1 (en) 1998-07-01
JP2000501067A (ja) 2000-02-02
WO1997007798A1 (en) 1997-03-06
EP0850057A4 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
CA2230540A1 (en) Pharmaceutical compounds
US6013626A (en) Cryptophycins from synthesis
US6680311B1 (en) Cryptophycin compounds
EP0934065B1 (en) Novel cryptophycin derivatives as anti-neoplastic agents
AU723652B2 (en) New cryptophycins from synthesis
CA2263420A1 (en) Pharmaceutical compounds
KR100459527B1 (ko) 합성된신규한크립토파이신
EP0923564A1 (en) Pharmaceutical compounds
US20020128185A1 (en) Pharmaceutical compounds
CA2241086A1 (en) Pharmaceutical compounds
US5955423A (en) Cryptophycins
MXPA98001604A (en) Farmaceuti compounds
RU2195458C2 (ru) Криптофициновое соединение, фармацевтическая композиция, способ ингибирования пролиферации клеток и способ смягчения патологического состояния
CA2214565C (en) New cryptophycins from synthesis
AU716025B2 (en) New cryptophycins
KR100505779B1 (ko) 제약 화합물
MXPA02007995A (es) Derivados de tetrahidrofurilo sustituidos por oxy y amino con actividad antitumoral.
MXPA99001825A (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FZDE Dead